Zebrafish: A trending model for gut-brain axis investigation

Zebrafish (Danio rerio) has ascended as a pivotal model organism in the realm of gut-brain axis research, principally owing to its high-throughput experimental capabilities and evolutionary alignment with mammals. The inherent transparency of zebrafish embryos facilitates unprecedented real-time imaging, affording unparalleled insights into the intricate dynamics of bidirectional communication between the gut and the brain. Noteworthy are the structural and functional parallels shared between the zebrafish and mammalian gut-brain axis components, rendering zebrafish an invaluable model for probing the molecular and cellular intricacies inherent in this critical physiological interaction. Recent investigations in zebrafish have systematically explored the impact of gut microbiota on neurodevelopment, behaviour, and disease susceptibility, underscoring the model's prowess in unravelling the multifaceted influence of microbial communities in shaping gut-brain interactions. Leveraging the genetic manipulability inherent in zebrafish, researchers have embarked on targeted explorations of specific pathways and molecular mechanisms, providing nuanced insights into the fundamental functioning of the gut-brain axis. This comprehensive review synthesizes pivotal findings and methodological advancements derived from zebrafish-based gut-brain axis research, accentuating the model's potential to significantly advance our understanding of this complex interplay. Furthermore, it underscores the translational significance of these insights, offering promising avenues for the identification of therapeutic targets in neuro-gastroenterological disorders and psychiatric conditions intricately linked with gut-brain interactions.

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

This analysis explores the principal regulatory concerns linked to nanomedicines and gene vaccines, including the complexities involved and the perspectives on how to navigate them. In the realm of nanomedicines, ensuring the safety of nanomaterials is paramount due to their unique characteristics and potential interactions with biological systems. Regulatory bodies are actively formulating guidelines and standards to assess the safety and risks associated with nanomedicine products, emphasizing the need for standardized characterization techniques to accurately gauge their safety and effectiveness. Regarding gene vaccines, regulatory frameworks must be tailored to address the distinct challenges posed by genetic interventions, necessitating special considerations in safety and efficacy evaluations, particularly concerning vector design, target specificity, and long-term patient monitoring. Ethical concerns such as patient autonomy, informed consent, and privacy also demand careful attention, alongside the intricate matter of intellectual property rights, which must be balanced against the imperative of ensuring widespread access to these life-saving treatments. Collaborative efforts among regulatory bodies, researchers, patent offices, and the private sector are essential to tackle these challenges effectively, with international cooperation being especially crucial given the global scope of nanomedicine and genetic vaccine development. Striking the right balance between safeguarding intellectual properties and promoting public health is vital for fostering innovation and ensuring equitable access to these ground-breaking technologies, underscoring the significance of addressing these regulatory hurdles to fully harness the potential benefits of nanomedicine and gene vaccines for enhancing healthcare outcomes on a global scale. STATEMENT OF SIGNIFICANCE: Several biomaterials are being proposed for the development of nanovaccines, from polymeric micelles, PLGA-/PEI-/PLL-nanoparticles, solid lipid nananoparticles, cationic lipoplexes, liposomes, hybrid materials, dendrimers, carbon nanotubes, hydrogels, to quantum dots. Lipid nanoparticles (LNPs) have gained tremendous attention since the US Food and Drug Administration (FDA) approval of Pfizer and Moderna's COVID-19 vaccines, raising public awareness to the regulatory challenges associated with nanomedicines and genetic vaccines. This review provides insights into the current perspectives and potential strategies for addressing these issues, including clinical trials. By navigating these regulatory landscapes effectively, we can unlock the full potential of nanomedicine and genetic vaccines using a range of promising biomaterials towards improving healthcare outcomes worldwide.

Revisiting microbial exopolysaccharides: a biocompatible and sustainable polymeric material for multifaceted biomedical applications

Microbial exopolysaccharides (EPS) have gained significant attention as versatile biomolecules with multifarious applications across various sectors. This review explores the valorisation of EPS and its potential impact on diverse sectors, including food, pharmaceuticals, cosmetics, and biotechnology. EPS, secreted by microorganisms, possess unique physicochemical properties, such as high molecular weight, water solubility, and biocompatibility, making them attractive for numerous functional roles. Additionally, EPS exhibit significant bioactivity, contributing to their potential use in pharmaceuticals for drug delivery and tissue engineering applications. Moreover, the eco-friendly and sustainable nature of microbial EPS production aligns with the growing demand for environmentally conscious processes. However, challenges still exist in large-scale production, purification, and regulatory approval for commercial use. Advances in bioprocessing and microbial engineering offer promising solutions to overcome these hurdles. Stringent investigations have concluded EPS as novel sources for sustainable applications that are likely to emerge and develop, further reinforcing the significance of these biopolymers in addressing contemporary societal needs and driving innovation in various industrial sectors. Overall, the microbial EPS represents a thriving field with immense potential for meeting diverse industrial demands and advancing sustainable technologies.

Noxious ramifications of cosmetic pollutants on gastrointestinal microbiome: A pathway to neurological disorders

On exposure to cosmetic pollutants, gastrointestinal dysbiosis, which is characterised by a disturbance in the gut microbiota, has come into focus as a possible contributor to the occurrence of neurotoxic consequences. It is normal practice to use personal care products that include parabens, phthalates, sulphates, triclosans/triclocarbans and micro/nano plastics. These substances have been found in a variety of bodily fluids and tissues, demonstrating their systemic dispersion. Being exposed to these cosmetic pollutants has been linked in recent research to neurotoxicity, including cognitive decline and neurodevelopmental problems. A vital part of sustaining gut health and general well-being is the gut flora. Increased intestinal permeability, persistent inflammation, and impaired metabolism may result from disruption of the gut microbial environment, which may in turn contribute to neurotoxicity. The link between gastrointestinal dysbiosis and the neurotoxic effects brought on by cosmetic pollutants may be explained by a number of processes, primarily the gut-brain axis. For the purpose of creating preventative and therapeutic measures, it is crucial to comprehend the intricate interactions involving cosmetic pollutants, gastrointestinal dysbiosis, and neurotoxicity. This review provides an in-depth understanding of the various hazardous cosmetic pollutants and its potential role in the occurrence of neurological disorders via gastrointestinal dysbiosis, providing insights into various described and hypothetical mechanisms regarding the complex toxic effects of these industrial pollutants.